eFoodSafety Formulates All-Natural Antibiotic ``Proxorin(TM)''

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: MRSA / Drug Resistance
Article Date: 05 Mar 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

eFoodSafety.com, Inc. (OTCBB: EFSF, http://www.efoodsafety.com), through its wholly-owned subsidiary Knock-Out Technologies Ltd., has developed and will begin clinical testing of Proxorin™, based on the company's CitroxinTM formula, for use as a natural antibiotic/anti-microbial for treatment against a broad spectrum of common bacterial pathogens. Unlike many antibiotics, which often have a limited range of applications, Proxorin's natural composition allows it to be used in a range of conditions where anti-microbials are needed.

As an antibiotic, Proxorin can offer several advantages over common drug-based antibiotics. Its ability to confer its benefits against both gram-negative and gram-positive bacteria enables it to be used to treat a broad spectrum of bacterial pathogens. Proxorin also produces far fewer side effects than other common antibiotic pharmaceuticals, thereby reducing the likelihood of rebound infections. In addition, Proxorin can provide benefits to those patients who experience allergic reactions to a spectrum of "cillin" drugs. Finally, an enormous problem for the normal armament of antibiotics is the potential for "bugs" to develop resistance to the beneficent effects of a given antibiotic-a scenario that is highly unlikely to occur with Proxorin.

Initial microbial inhibition tests prove Proxorin extremely effective in eradicating MRSA, the methicillin resistant form of Staphylococcus aurous, and other studies of the formula show a 100% kill rate for common bacteria including: eFoodSafety expects to offer the antibiotic both as a high potency pill for oral ingestion and as a trans-dermal cream. These two forms utilize proprietary technology to offer controlled and targeted release of the active compounds to ensure maximum bio-availability and benefits.

"The decision to conduct clinical testing of Proxorin as a natural antibiotic is based on the encouraging microbial inhibition test results showing its ability to eradicate MRSA as other common bacterial pathogens," says Robert Bowker, President of Knock-Out Technologies. "These widespread bacterial pathogens are becoming increasingly difficult and expensive to defeat using conventional pharmaceutical methods. Importantly, eFoodSafety can offer Proxorin as both a high potency pill for oral ingestion and as a trans-dermal cream that provides effective absorption without having to go through normal digestion. We believe that with positive clinical results, our natural treatment can provide a superior solution to patients seeking treatment."

About eFoodSafety.com, Inc.

efoodsafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin™ (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product, which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture, is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.

The Company is the owner of Cinnergen™, a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism available for sale at (http://www.cinnergen.com) and through national retailers; and Cinnechol™, a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.

The company's iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar™, a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body's immune system. The product contains Citroxin™, eFoodSafety's proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar™ is available in three delicious flavors: chocolate, oatmeal-raisin, and orange-apple and can be purchased at http://www.immuneboost.com.

The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn™-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (http://www.talsyn.com), as well as seven (7) other products in the Talsyn™ line.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking statements." Such forward-looking statements are sometimes identified by words such as "intends," "anticipates," "believes," "expects" and "hopes." The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

http://www.efoodsafety.com